Jennifer Zimmer

The mechanics of organizational speed, and why momentum is the result of deliberate design.

Amid unrest, companies often scale back innovation. But instead of dropping anchor, adjust your sails to surge ahead.

Pricing, Patents and Progress: Navigating Biopharma’s biggest hurdles.

Reimagining a strained healthcare system to deliver higher-quality care worldwide and a more customer-centric future.

Despite the risks, brands will continue to seek a celebrity spokesperson. If the partnership sours, what is the right time to cut—and how?

It is no secret that the pharmaceutical industry is filled with a litany of unique challenges and regulations. In our experience — having chiseled away an expertise in this arena…

In our previous discussion, we talked about how to reveal and address the background conversations that prohibit an undeniable commitment to goals and project timelines — the first essential step in accelerating…

A pharmaceutical company failing in the recruitment for phase III trial of an important new drug was ready to cancel the trial. The tight criteria for administering the medication now…

The Challenge A biopharmaceutical company’s new drug in the works could greatly help people with motor function impairment. It was exciting. It was also behind schedule. The cross functional team…

Challenge: A Fortune 100 pharmaceutical company’s product development division was entering the clinical trials phase of a new drug development process. A number of competitors were in development on similar…

A large pharmaceutical company needed to bring together a new team within a key business unit. This team was tasked with developing a diverse collection of compound opportunities at different…

A bio-pharmaceutical company was facing a seemingly “impossible” timeline. They needed to file a submission to the FDA by the end of the first quarter. When Insigniam’s management consultants interviewed…